Share Price | Rekvina Labs Ltd Stock Analysis & Recommendation

Q: Why is Rekvina Labs Ltd falling/rising?

As of 09-Jun, Rekvina Labs Ltd's stock price is currently at 40.61, reflecting a decrease of 0.82, or 1.98%. The stock has underperformed its sector by 2.79% today, indicating a weaker performance relative to its peers. Over the past week, the stock has declined by 7.70%, while the benchmark Sensex has only decreased by 0.98%. This suggests that the stock is facing significant selling pressure compared to the broader market.Additionally, there has been erratic trading behavior, as the stock did not trade on one day out of the last 20 days. Investor participation appears to be falling, with a notable drop in delivery volume, which fell by 99.96% on June 4 compared to the 5-day average. This decline in trading activity may indicate a lack of investor confidence or interest in the stock.Despite being higher than the 20-day, 50-day, 100-day, and 200-day moving averages, the stock is lower than its 5-day moving average, which could signal a short-term downward trend. Overall, these factors contribute to the current decline in Rekvina Labs Ltd's stock price.

Q: Are Rekvina Labs Ltd latest results good or bad?

Rekvina Labs Ltd's latest results present a mixed picture. On one hand, there has been a notable improvement in certain metrics; for instance, the company reported a revenue of ₹0.72 crores in Q4 FY26, which is a significant sequential growth of 105.71% compared to the previous quarter. Additionally, the net loss has improved by 50% quarter-over-quarter, now standing at ₹0.06 crores. The operating margin has also shown improvement, moving from -34.29% to -8.33%.However, despite these positive changes, the company continues to face significant challenges. It has a negative book value, meaning its liabilities exceed its assets, which raises serious concerns about its financial health. The persistent net losses and lack of a clear path to profitability indicate ongoing operational difficulties. Moreover, the stock has experienced considerable volatility and has declined significantly over the past month, reflecting growing investor skepticism.Overall, while there are signs of improvement in revenue and loss reduction, the fundamental issues regarding profitability and financial stability remain a concern, leading to a cautious outlook on the company's performance.

Q: Should I buy, sell or hold Rekvina Labs Ltd?

Based on the current situation of Rekvina Labs Ltd, it would be advisable to sell your shares. The company is facing significant challenges, including a negative book value of Rs 0.33 crore and weak long-term fundamental strength. Additionally, there has been poor growth in net sales and operating profit over the past five years, with both metrics showing little to no improvement.The negative EBITDA of Rs -0.14 crore indicates that the company is struggling to generate earnings before interest, taxes, depreciation, and amortization, which adds to the risk associated with holding this stock. Given these factors, it seems prudent to consider selling rather than holding or buying more shares.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

12 (-99.24%) Volume

Shareholding (Mar 2026)

FII

0.00%

Held by 0 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

41.30%

Which are the latest news on Rekvina Labs?

09-Jun-2026

Are Rekvina Labs Ltd latest results good or bad?
Rekvina Labs Q4 FY26: Losses Deepen Despite Revenue Revival in Struggling Micro-Cap Pharma

Why is Rekvina Labs Ltd falling/rising?

09-Jun-2026

As of 09-Jun, Rekvina Labs Ltd's stock price is at 40.61, down 1.98% and underperforming its sector by 2.79%. The stock has seen significant selling pressure, with a 7.70% decline over the past week and a notable drop in investor participation.

View full answer

Are Rekvina Labs Ltd latest results good or bad?

22-May-2026

Rekvina Labs Ltd's latest results show mixed performance, with a 105.71% revenue increase and a 50% reduction in net loss, but ongoing challenges like negative book value and persistent losses raise concerns about its financial stability and profitability. Overall, the outlook remains cautious despite some positive metrics.

View full answer

Should I buy, sell or hold Rekvina Labs Ltd?

21-May-2026

When is the next results date for Rekvina Labs Ltd?

19-May-2026

The next results date for Rekvina Labs Ltd is 21 May 2026.

View full answer

Compare Rekvina Labs with Similar Stocks

Sun Pharma.Inds.Cresanto Global Divi's Lab.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Net Sales has grown by an annual rate of % and Operating profit at 0% over the last 5 years
The company has a negative book value of Rs 0.33 crore

Flat results in Mar 26

Risky - Negative EBITDA

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Drugs

Market cap

INR 25 Cr (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.22

Return on Equity

25.00%

Price to Book

-24.97

Revenue and Profits:

Net Sales:

1 Cr

(Quarterly Results - Mar 2026)

Net Profit:

0 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

35.82%

6 Months

0.0%

1 Year

0.0%

2 Years

0.0%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Rekvina Labs for the last several years.

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

Are Rekvina Labs Ltd latest results good or bad?

Rekvina Labs Ltd's latest financial results for Q4 FY26 indicate a complex situation characterized by both operational challenges and some signs of sequential improvement. The company reported net sales of ₹0.72 crores, which reflects a significant sequential growth of 105.71% from ₹0.35 crores in the previous quarter. This marks a notable recovery in revenue generation, as the company had previously reported zero sales in earlier quarters. Despite the increase in revenue, Rekvina Labs continues to face persistent profitability issues, reporting a net loss of ₹0.06 crores, although this represents a 50% improvement from the loss of ₹0.12 crores in Q3 FY26. The operating margin also showed some improvement, moving from -34.29% in Q3 FY26 to -8.33% in the latest quarter. This suggests that while the company is managing to grow its revenue, it still struggles to achieve positive operating cash flow. The mark...

Read full news article

Rekvina Labs Q4 FY26: Losses Deepen Despite Revenue Revival in Struggling Micro-Cap Pharma

Rekvina Labs Limited, a micro-cap pharmaceutical contract manufacturer with a market capitalisation of ₹20.00 crores, reported a net loss of ₹0.06 crores for Q4 FY26 (Mar'26), marking a 50.00% reduction in losses compared to the previous quarter's ₹0.12 crores loss. Whilst the company demonstrated sequential revenue growth of 105.71% to reach ₹0.72 crores in Q4 FY26, the persistent inability to achieve profitability and negative operating margins continue to raise serious concerns about the viability of its business model.

Read full news article

When is the next results date for Rekvina Labs Ltd?

The next results date for Rekvina Labs Ltd is scheduled for 21 May 2026....

Read full news article

Announcements

Board Meeting Outcome for Outcome Of Board Meeting Held On 21St May 2026

21-May-2026 | Source : BSE

Pursuant to Reg 33 read with Part A of Schedule III of SEBI (LODR) Regulation 2015 we hereby submitting the following: 1. Standalone Audited Financial Results for the Quarter ended and Year ended on March 31 2026 along with Assets & Liability Statement & Cash Flow Statement with Independent Auditor Report 2. Declaration of Auditor Report with unmodified Opinion pursuant to Reg 33 (3)(d) of Listing Regulations signed by Mr. Amit Shah Director of the Company.

Financial Results For Quarter Ended & Year Ended On March 31 2026.

21-May-2026 | Source : BSE

Standalone Audited Financial Results for the Quarter ended & Year ended on March 31 2026 along with statement of Assets & Liabilities Cash Flow statement & unmodified Audit Report.

Board Meeting Intimation for Consider And Approve Financial Result For The QTR 4

18-May-2026 | Source : BSE

Rekvina Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 inter alia to consider and approve Financial Result for the Quarter and Year ended 31.03.2026

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

No Dividend history available

SPLITS

Rekvina Labs Ltd has announced 5:10 stock split, ex-date: 30 Apr 14

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.00%

EBIT Growth (5y)

0.00%

EBIT to Interest (avg)

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.22

Sales to Capital Employed (avg)

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

-1.49%

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-24.48

EV to EBIT

-24.70

EV to EBITDA

-24.70

EV to Capital Employed

-24.70

EV to Sales

19.45

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Non Institution

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Surbhit Mukesh Shah (15.22%)

Highest Public shareholder

Viralkumar Tribhovandas Patel (4.388%)

Individual Investors Holdings

45.88%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 105.71% vs 75.00% in Dec 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 50.00% vs -300.00% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.72",
          "val2": "0.35",
          "chgp": "105.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.06",
          "val2": "-0.12",
          "chgp": "50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.06",
          "val2": "-0.12",
          "chgp": "50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-8.33%",
          "val2": "-34.29%",
          "chgp": "25.96%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "alert": "No Half Yearly Results declared by Rekvina Labs"
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "alert": "No Nine Monthly Results declared by Rekvina Labs"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is -78.57% vs -75.00% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.27",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.25",
          "val2": "-0.14",
          "chgp": "-78.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.25",
          "val2": "-0.14",
          "chgp": "-78.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-19.69%",
          "val2": "0.00%",
          "chgp": "-19.69%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ

Mar'26

Dec'25

Change(%)

Net Sales

0.72

0.35

105.71%

Operating Profit (PBDIT) excl Other Income

-0.06

-0.12

50.00%

Interest

0.00

Exceptional Items

0.00

Standalone Net Profit

-0.06

-0.12

50.00%

Operating Profit Margin (Excl OI)

-8.33%

-34.29%

25.96%

Values in Rs Cr.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2026 is 105.71% vs 75.00% in Dec 2025

Standalone Net Profit

QoQ Growth in quarter ended Mar 2026 is 50.00% vs -300.00% in Dec 2025

All Quarterly Results

Annual Results Snapshot (Standalone) - Mar'26

Mar'26

Mar'25

Change(%)

Net Sales

1.27

0.00

Operating Profit (PBDIT) excl Other Income

-0.25

-0.14

-78.57%

Interest

0.00

Exceptional Items

0.00

Standalone Net Profit

-0.25

-0.14

-78.57%

Operating Profit Margin (Excl OI)

-19.69%

0.00%

-19.69%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2026 is 0.00% vs 0.00% in Mar 2025

Standalone Net Profit

YoY Growth in year ended Mar 2026 is -78.57% vs -75.00% in Mar 2025

All Annual Results

Company CV

About Rekvina Labs Ltd

Rekvina Labs Ltd

Micro Cap

Pharmaceuticals & Drugs

Rekvina Labs Limited was incorporated on 1st November 1988. From a small domestic company at inception in middle of 80's, Rekvina has grown formidably to be an integrated, Indian pharmaceutical company with sales in excess of Rs 20 Crore. It is registered in England and Wales as a Public Limited Company. The Company is a Quality producer of Pharmaceutical formulations for its customer as per their specific requirements. It provide contract research and manufacturing services to customers.

Company Coordinates

Company Details

328 Paradise Complex, Sayajigunj Vadodara Gujarat : 390005

Tel: 91-265-2362966

http://www.rekvinalaboratories.com

rekvina@gmail.com

Registrar Details

Purva Shareregistry (India) Pvt Ltd , Gala No 9, Shiv Shakti, Industrial Estate,Sitaram Mill Comp., J R Boricha Marg, Lower Parel [E], Mumbai